{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:49:48Z","timestamp":1794854988368,"version":"4.9.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Epstein-Barr Virus (EBV)-associated nasopharyngeal carcinoma (NPC) exhibits unusual geographic restriction despite ubiquitous lifelong infection. Screening programs can detect most NPC cases at an early stage, but existing EBV diagnostics are limited by false positives and low positive predictive value (PPV), leading to excess screening endoscopies, MRIs, and repeated testing. Recent EBV genome-wide association studies (GWAS) suggest that EBV <jats:italic>BALF2<\/jats:italic> variants account for more than 80% of attributable NPC risk. We therefore hypothesized that high-risk <jats:italic>BALF2<\/jats:italic> variants could be readily detected in plasma for once-lifetime screening triage.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We designed and validated a multiplex genotyping assay to detect EBV <jats:italic>BALF2<\/jats:italic> polymorphisms in human plasma. Targeted next-generation sequencing was used to validate this assay, conduct association studies with clinical phenotype, and longitudinally genotype plasma to assess within-host haplotype stability. We examined the association between NPC and <jats:italic>BALF2<\/jats:italic> haplotypes in a large non-endemic population and three prior EBV GWAS. Finally, we estimated NPC mortality reduction, resource utilization, and cost-effectiveness of <jats:italic>BALF2<\/jats:italic> variant-informed screening using a previously-validated cohort model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Following analytical validation, the <jats:italic>BALF2<\/jats:italic> genotyping assay had 99.3% concordance with sequencing in a cohort of 24 NPC cases and 155 non-NPC controls. <jats:italic>BALF2<\/jats:italic> haplotype was highly associated with NPC in this non-endemic population (I613V: odds ratio [OR] 7.9; V317M: OR 178.8). No other candidate <jats:italic>BALF2<\/jats:italic> polymorphisms were significantly associated with NPC or hematologic disorders.<\/jats:p>\n                <jats:p>Longitudinal genotyping revealed 97.8% within-host haplotype concordance, indicative of lifelong latent infection. In a meta-analysis of 755 NPC cases and 981 non-NPC controls, <jats:italic>BALF2<\/jats:italic> I613V and V317M were significantly associated with NPC in both endemic and non-endemic populations.<\/jats:p>\n                <jats:p>Modeled variant-informed screening strategies achieved a 46% relative increase in PPV with 7% decrease in effective screening sensitivity, thereby averting nearly half of screening endoscopies\/MRIs among endemic populations in east\/southeast Asia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>EBV <jats:italic>BALF2<\/jats:italic> haplotypes are temporally stable within hosts and can be readily detected in plasma via an inexpensive multiplex genotyping assay that offers near-perfect sequencing concordance. In endemic and non-endemic populations, I613V and V317M were highly associated with NPC and could be leveraged to develop variant-informed screening programs that mitigate false positives with small reductions in screening sensitivity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12943-022-01625-6","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T11:03:46Z","timestamp":1659006226000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Multiplex Epstein-Barr virus BALF2 genotyping detects high-risk variants in plasma for population screening of nasopharyngeal carcinoma"],"prefix":"10.1186","volume":"21","author":[{"given":"Jacob A.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malaya K.","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ChunHong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Zehnder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quynh-Thu","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Pinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"key":"1625_CR1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jcv.2018.03.001","volume":"102","author":"SK Dunmire","year":"2018","unstructured":"Dunmire SK, Verghese PS, Balfour HH. Primary Epstein-Barr virus infection. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2018;102:84\u201392. https:\/\/doi.org\/10.1016\/j.jcv.2018.03.001.","journal-title":"J Clin Virol Off Publ Pan Am Soc Clin Virol"},{"issue":"3","key":"1625_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"1625_CR3","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/cncr.29795","volume":"122","author":"JJ Pan","year":"2016","unstructured":"Pan JJ, Ng WT, Zong JF, et al. Proposal for the 8th edition of the AJCC\/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer. 2016;122(4):546\u201358. https:\/\/doi.org\/10.1002\/cncr.29795.","journal-title":"Cancer."},{"issue":"6","key":"1625_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa1701717","volume":"377","author":"KCA Chan","year":"2017","unstructured":"Chan KCA, Woo JKS, King A, et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med. 2017;377(6):513\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1701717.","journal-title":"N Engl J Med"},{"issue":"10","key":"1625_CR5","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1093\/annonc\/mdz231","volume":"30","author":"MF Ji","year":"2019","unstructured":"Ji MF, Sheng W, Cheng WM, et al. Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China. Ann Oncol. 2019;30(10):1630\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdz231.","journal-title":"Ann Oncol"},{"issue":"1","key":"1625_CR6","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1038\/s41467-019-11226-5","volume":"10","author":"WKJ Lam","year":"2019","unstructured":"Lam WKJ, Jiang P, Chan KCA, et al. Methylation analysis of plasma DNA informs etiologies of Epstein-Barr virus-associated diseases. Nat Commun. 2019;10(1):3256. https:\/\/doi.org\/10.1038\/s41467-019-11226-5.","journal-title":"Nat Commun"},{"issue":"7","key":"1625_CR7","doi-asserted-by":"publisher","first-page":"e0132669","DOI":"10.1371\/journal.pone.0132669","volume":"10","author":"Y Chen","year":"2015","unstructured":"Chen Y, Zhao W, Lin L, et al. Nasopharyngeal Epstein-Barr virus load: an efficient supplementary method for population-based nasopharyngeal carcinoma screening. PLoS One. 2015;10(7):e0132669. https:\/\/doi.org\/10.1371\/journal.pone.0132669.","journal-title":"PLoS One"},{"issue":"1","key":"1625_CR8","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/1055-9965.EPI-15-0144","volume":"25","author":"JX Bei","year":"2016","unstructured":"Bei JX, Su WH, Ng CC, et al. A GWAS meta-analysis and replication study identifies a novel locus within CLPTM1L\/TERT associated with nasopharyngeal carcinoma in individuals of Chinese ancestry. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2016;25(1):188\u201392. https:\/\/doi.org\/10.1158\/1055-9965.EPI-15-0144.","journal-title":"Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol"},{"issue":"7","key":"1625_CR9","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41588-019-0436-5","volume":"51","author":"M Xu","year":"2019","unstructured":"Xu M, Yao Y, Chen H, et al. Genome sequencing analysis identifies Epstein-Barr virus subtypes associated with high risk of nasopharyngeal carcinoma. Nat Genet. 2019;51(7):1131\u20136. https:\/\/doi.org\/10.1038\/s41588-019-0436-5.","journal-title":"Nat Genet"},{"issue":"4","key":"1625_CR10","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1093\/clinchem\/hvaa027","volume":"66","author":"WKJ Lam","year":"2020","unstructured":"Lam WKJ, Ji L, Tse OYO, et al. Sequencing analysis of plasma Epstein-Barr virus DNA reveals nasopharyngeal carcinoma-associated single nucleotide variant profiles. Clin Chem. 2020;66(4):598\u2013605. https:\/\/doi.org\/10.1093\/clinchem\/hvaa027.","journal-title":"Clin Chem"},{"issue":"12","key":"1625_CR11","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1002\/ijc.32049","volume":"144","author":"KF Hui","year":"2019","unstructured":"Hui KF, Chan TF, Yang W, et al. High risk Epstein-Barr virus variants characterized by distinct polymorphisms in the EBER locus are strongly associated with nasopharyngeal carcinoma. Int J Cancer. 2019;144(12):3031\u201342. https:\/\/doi.org\/10.1002\/ijc.32049.","journal-title":"Int J Cancer"},{"issue":"10","key":"1625_CR12","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1128\/JCM.01676-14","volume":"52","author":"J Abeynayake","year":"2014","unstructured":"Abeynayake J, Johnson R, Libiran P, et al. Commutability of the Epstein-Barr virus WHO international standard across two quantitative PCR methods. J Clin Microbiol. 2014;52(10):3802\u20134. https:\/\/doi.org\/10.1128\/JCM.01676-14.","journal-title":"J Clin Microbiol"},{"issue":"8","key":"1625_CR13","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1158\/1078-0432.CCR-12-3702","volume":"19","author":"QT Le","year":"2013","unstructured":"Le QT, Zhang Q, Cao H, et al. An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19(8):2208\u201315. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3702.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"7","key":"1625_CR14","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1093\/jnci\/djaa198","volume":"113","author":"JA Miller","year":"2021","unstructured":"Miller JA, Le QT, Pinsky BA, Wang H. Cost-effectiveness of nasopharyngeal carcinoma screening with Epstein-Barr virus polymerase chain reaction or serology in high-incidence populations worldwide. J Natl Cancer Inst. 2021;113(7):852\u201362. https:\/\/doi.org\/10.1093\/jnci\/djaa198.","journal-title":"J Natl Cancer Inst"},{"key":"1625_CR15","doi-asserted-by":"publisher","unstructured":"Kondo S, Okuno Y, Murata T, et al. EBV genome variations enhance clinicopathological features of nasopharyngeal carcinoma in a non-endemic region. Cancer Sci. 2022;29. https:\/\/doi.org\/10.1111\/cas.15381 Published online April.","DOI":"10.1111\/cas.15381"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-022-01625-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-022-01625-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-022-01625-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T11:04:19Z","timestamp":1659006259000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-022-01625-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1625"],"URL":"https:\/\/doi.org\/10.1186\/s12943-022-01625-6","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"assertion":[{"value":"28 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted with Stanford University institutional review board approval. Individual consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests related to this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"154"}}